

**Question for written answer E-002128/2019
to the Commission**

Rule 130

Nessa Childers (S&D) and Kateřina Konečná (GUE/NGL)

Subject: Access to innovative treatment and care in the EU

Persistent health inequalities remain, across and within the Member States; this issue is considered an urgent priority for the EU health policy agenda. In recent years, the lack of access to treatment and care (including dietary, pharmacological treatment and long-term care) has been increasingly recognised as an important factor in combating health inequalities, since the lack of access results in poorer health outcomes and a lower quality of life.

As Members of the European Parliament, we believe that patients across the EU – in particular those faced with considerable unmet needs e.g. people living with rare diseases – are entitled to equal access and opportunities so they can enjoy the highest attainable quality of health services and care.

Can the Commission indicate how it is responding to increasing calls – from patients, healthcare professionals and other key health and social stakeholders – for better and equal access to treatment and care, including innovative and personalised medicinal products?